ZIPRASIDONE caps:

Class: Atypical antipsychotic Agent

Indications: Treatment of schizophrenia; treatment of acute manic or mixed episodes associated with bipolar disorder with or without psychosis; maintenance treatment of bipolar disorder as an adjunct to lithium or valproate; acute agitation in patients with schizophrenia,Psychosis/agitation related to Alzheimer's dementia

Available dosage form in the hospital: CAP (40MD, 60MG, 80MG)

Dosage:

-**Bipolar mania (acute):** Oral: Initial: 40 mg twice daily

Adjustment: May increase to 60 mg or 80 mg twice daily on second day of treatment; average dose 40-80 mg twice daily.

-**Bipolar disorder (maintenance; as adjunct to lithium or valproate):** Oral: Continue ziprasidone dose at which the patient was initially stabilized; usual dosage range: 40-80 mg twice daily

-**Schizophrenia:** Oral: Initial: 20 mg twice daily (U.S. labeling) or 20-40 mg twice daily (Canadian labeling)

-*Adjustment:* Increases (if indicated) should be made no more frequently than every 2 days; ordinarily patients should be observed for improvement over several weeks before adjusting the dose.

-*Maintenance:* Range: 20-100 mg twice daily; however, dosages >80 mg twice daily are generally not recommended.

-**Acute agitation (schizophrenia):** I.M.: 10 mg every 2 hours **or** 20 mg every 4 hours (maximum: 40 mg daily). Oral therapy should replace I.M. administration as soon as possible.

Geriatric

No dosage adjustment is recommended; consider initiating at a low end of the dosage range, with slower titration.

Renal Impairment:

-Oral: No dosage adjustment is recommended

-I.M.: Cyclodextrin, an excipient in the I.M. formulation, is cleared by renal filtration; use with caution. Ziprasidone is not removed by hemodialysis.

Hepatic Impairment:

**U.S. labeling*: No dosage adjustment is recommended; however, drug undergoes extensive hepatic metabolism and systemic exposure may be increased. Use with caution.

**Canadian labeling*: Manufacturer labeling suggests that dose reductions should be considered but does not provide specific dosing recommendations.

Common side effect:

Central nervous system: Extrapyramidal symptoms (2% to 31%), somnolence (8% to 31%), headache (3% to 18%), dizziness (3% to 16%)

Gastrointestinal: Nausea (4% to 12%)

Pregnancy Risk Factor: C